Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31096165 | 0.84 | STK17B (0.41) | MGLL | |
| SCHEMBL24407526 | 0.84 | STK17B (0.41) | MGLL | |
| SCHEMBL31096322 | 0.78 | KMT2A (0.42) | HDAC6EGLN1GRM2MAPTALDH1A1 | |
| SCHEMBL23850234 | 0.78 | KMT2A (0.42) | HDAC6EGLN1GRM2MAPTALDH1A1 | |
| SCHEMBL31096344 | 0.74 | KDM4E (0.42) | GRM2ALDH1A1KDM4EPOLB | |
| SCHEMBL24407574 | 0.74 | KDM4E (0.42) | GRM2ALDH1A1KDM4EPOLB | |
| SCHEMBL30578895 | 0.69 | PDE3B (0.33) | — | |
| SCHEMBL23853643 | 0.69 | PDE3B (0.33) | — | |
| SCHEMBL25321271 | 0.69 | TIPARP (0.33) | HDAC1HDAC6MGLL | |
| SCHEMBL27136921 | 0.68 | STING1 (0.47) | EGLN1GRM2LMNAKDM4ETNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883553-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3883567-A1 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFlection Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |